Logo image of TXG

10X GENOMICS INC-CLASS A (TXG) Stock Fundamental Analysis

NASDAQ:TXG - Nasdaq - US88025U1097 - Common Stock - Currency: USD

12.06  -2.19 (-15.37%)

Premarket: 12.19 +0.13 (+1.08%)

Fundamental Rating

3

TXG gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. TXG has a great financial health rating, but its profitability evaluates not so good. TXG is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TXG has reported negative net income.
In the past year TXG had a positive cash flow from operations.
TXG had negative earnings in each of the past 5 years.
TXG had negative operating cash flow in 4 of the past 5 years.
TXG Yearly Net Income VS EBIT VS OCF VS FCFTXG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 -100M -200M -300M -400M -500M

1.2 Ratios

TXG's Return On Assets of -19.47% is on the low side compared to the rest of the industry. TXG is outperformed by 61.40% of its industry peers.
TXG's Return On Equity of -25.26% is in line compared to the rest of the industry. TXG outperforms 45.61% of its industry peers.
Industry RankSector Rank
ROA -19.47%
ROE -25.26%
ROIC N/A
ROA(3y)-16.09%
ROA(5y)-22.37%
ROE(3y)-20.72%
ROE(5y)-28.6%
ROIC(3y)N/A
ROIC(5y)N/A
TXG Yearly ROA, ROE, ROICTXG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300 -400

1.3 Margins

TXG has a better Gross Margin (66.63%) than 96.49% of its industry peers.
In the last couple of years the Gross Margin of TXG has declined.
TXG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.32%
GM growth 5Y-3.84%
TXG Yearly Profit, Operating, Gross MarginsTXG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

More info and screens

7

2. Health

2.1 Basic Checks

TXG does not have a ROIC to compare to the WACC, probably because it is not profitable.
TXG has more shares outstanding than it did 1 year ago.
TXG has more shares outstanding than it did 5 years ago.
There is no outstanding debt for TXG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TXG Yearly Shares OutstandingTXG Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
TXG Yearly Total Debt VS Total AssetsTXG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

TXG has an Altman-Z score of 2.63. This is not the best score and indicates that TXG is in the grey zone with still only limited risk for bankruptcy at the moment.
TXG's Altman-Z score of 2.63 is fine compared to the rest of the industry. TXG outperforms 61.40% of its industry peers.
There is no outstanding debt for TXG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 2.63
ROIC/WACCN/A
WACC11.51%
TXG Yearly LT Debt VS Equity VS FCFTXG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 4.90 indicates that TXG has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.90, TXG is doing good in the industry, outperforming 73.68% of the companies in the same industry.
A Quick Ratio of 4.12 indicates that TXG has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.12, TXG is in the better half of the industry, outperforming 70.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.9
Quick Ratio 4.12
TXG Yearly Current Assets VS Current LiabilitesTXG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

TXG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.90%, which is quite good.
Looking at the last year, TXG shows a small growth in Revenue. The Revenue has grown by 6.57% in the last year.
TXG shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 33.43% yearly.
EPS 1Y (TTM)19.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.03%
Revenue 1Y (TTM)6.57%
Revenue growth 3Y27.46%
Revenue growth 5Y33.43%
Sales Q2Q%-1.3%

3.2 Future

TXG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.43% yearly.
Based on estimates for the next years, TXG will show a small growth in Revenue. The Revenue will grow by 5.12% on average per year.
EPS Next Y34.1%
EPS Next 2Y18.64%
EPS Next 3Y16.4%
EPS Next 5Y17.43%
Revenue Next Year-2%
Revenue Next 2Y1.15%
Revenue Next 3Y3.73%
Revenue Next 5Y5.12%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TXG Yearly Revenue VS EstimatesTXG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TXG Yearly EPS VS EstimatesTXG Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TXG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TXG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TXG Price Earnings VS Forward Price EarningsTXG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

TXG's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. TXG is cheaper than 64.91% of the companies in the same industry.
Industry RankSector Rank
P/FCF 58.29
EV/EBITDA N/A
TXG Per share dataTXG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as TXG's earnings are expected to grow with 16.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.64%
EPS Next 3Y16.4%

More info and screens

0

5. Dividend

5.1 Amount

TXG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

10X GENOMICS INC-CLASS A

NASDAQ:TXG (2/10/2025, 8:27:20 PM)

Premarket: 12.19 +0.13 (+1.08%)

12.06

-2.19 (-15.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-29 2024-10-29/amc
Earnings (Next)02-12 2025-02-12/amc
Inst Owners97.06%
Inst Owner Change-56.25%
Ins Owners1.73%
Ins Owner Change0.05%
Market Cap1.46B
Analysts73.91
Price Target20.54 (70.32%)
Short Float %7.32%
Short Ratio4.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)23.44%
Min EPS beat(2)13.05%
Max EPS beat(2)33.83%
EPS beat(4)3
Avg EPS beat(4)8.67%
Min EPS beat(4)-13.26%
Max EPS beat(4)33.83%
EPS beat(8)4
Avg EPS beat(8)-3.72%
EPS beat(12)5
Avg EPS beat(12)-13.15%
EPS beat(16)8
Avg EPS beat(16)-99.59%
Revenue beat(2)1
Avg Revenue beat(2)-2.17%
Min Revenue beat(2)-5.35%
Max Revenue beat(2)1%
Revenue beat(4)1
Avg Revenue beat(4)-1.64%
Min Revenue beat(4)-5.35%
Max Revenue beat(4)1%
Revenue beat(8)5
Avg Revenue beat(8)0.68%
Revenue beat(12)7
Avg Revenue beat(12)-0.16%
Revenue beat(16)11
Avg Revenue beat(16)0.86%
PT rev (1m)-0.33%
PT rev (3m)-18.54%
EPS NQ rev (1m)-1.87%
EPS NQ rev (3m)-1.87%
EPS NY rev (1m)0.66%
EPS NY rev (3m)-0.54%
Revenue NQ rev (1m)3.96%
Revenue NQ rev (3m)3.96%
Revenue NY rev (1m)0.89%
Revenue NY rev (3m)0.9%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.32
P/FCF 58.29
P/OCF 37.27
P/B 2.02
P/tB 2.08
EV/EBITDA N/A
EPS(TTM)-1.53
EYN/A
EPS(NY)-1.29
Fwd EYN/A
FCF(TTM)0.21
FCFY1.72%
OCF(TTM)0.32
OCFY2.68%
SpS5.2
BVpS5.97
TBVpS5.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.47%
ROE -25.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.63%
FCFM 3.98%
ROA(3y)-16.09%
ROA(5y)-22.37%
ROE(3y)-20.72%
ROE(5y)-28.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.32%
GM growth 5Y-3.84%
F-Score5
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 38.36%
Cap/Sales 2.24%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.9
Quick Ratio 4.12
Altman-Z 2.63
F-Score5
WACC11.51%
ROIC/WACCN/A
Cap/Depr(3y)379.32%
Cap/Depr(5y)403.39%
Cap/Sales(3y)18.05%
Cap/Sales(5y)16.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.03%
EPS Next Y34.1%
EPS Next 2Y18.64%
EPS Next 3Y16.4%
EPS Next 5Y17.43%
Revenue 1Y (TTM)6.57%
Revenue growth 3Y27.46%
Revenue growth 5Y33.43%
Sales Q2Q%-1.3%
Revenue Next Year-2%
Revenue Next 2Y1.15%
Revenue Next 3Y3.73%
Revenue Next 5Y5.12%
EBIT growth 1Y25.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.06%
EBIT Next 3Y19.69%
EBIT Next 5Y23.64%
FCF growth 1Y115.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y194.35%
OCF growth 3YN/A
OCF growth 5YN/A